Victory Capital Management Inc. Has $54.11 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Victory Capital Management Inc. cut its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 332,119 shares of the company's stock after selling 6,747 shares during the period. Victory Capital Management Inc. owned approximately 0.07% of Zoetis worth $54,112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis during the third quarter worth approximately $33,000. Finally, Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Remove Ads

Zoetis Trading Up 1.8 %

Shares of NYSE:ZTS traded up $3.09 during mid-day trading on Friday, reaching $170.34. 3,296,788 shares of the company's stock were exchanged, compared to its average volume of 3,274,650. The firm has a market capitalization of $76.28 billion, a price-to-earnings ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. The business's fifty day moving average price is $166.72 and its 200-day moving average price is $176.78. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target on the stock. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.